Nanomedicine 

Overview

Nanomedicine is the interface of clinical medicine, pharmaceutics, regenerative medicine and nano(geno) toxicology. Increasing demand and awareness of nanotechnology applications in Medicine has lead to the emergence of Nanomedicine. Capitalising on the £22m infrastructure investment in the Centre for Nanohealth (CNH).

Suitable for anyone with a life sciences facing degree who is targeting industry facing employment in pharma or research careers through PhDs, students will tackle nano-enabled innovation in molecular medicine, drug development, advanced drug delivery and imaging/diagnostics. Pharmaceuticals and advanced therapeutics is embedded across these themes. In addition we have two focus areas, being Regenerative medicine (incorporating biomaterials) and nano(geno) toxicology which map to the core research themes of the School. These areas are furnished by expertise from the colleges of engineering and science, culminating in a multidisciplinary laboratory based research project underpinned by dedicated statistics/informatics modules and research design/ethics.

Career opportunities

A Nanomedicine programme at Swansea University is designed to equip our graduates with transferable skills that are highly valued in the workplace. Our research-led ethos ensures that students explore the frontiers of scientific knowledge, and the intensive practical components provide rigorous training in cutting edge technical skills that are used in the modern biosciences (scientific or clinical research career in the fields of nanomedicine and advanced therapeutics) while working in areas of world-leading expertise within the School.

The nanomedicine course appeals to all sectors in life sciences. We have students who have left the course and gone onto industry, academia (PhDs) and professional vocations.  Most do stay on in academia; some do a PhD in a more specific field related to nanomedicine, others go on to Graduate Entry Medicine.  Some have gone onto industry, with a range of biopharmaceutical to biotechnology companies in the fields of drug/technology testing and development.